title: When is a cost-effectiveness claim valid? How much should the FDA care?
abstract: Federal law requires the Food and Drug Administration (FDA) to regulate the promotional claims of prescription drugs and certain devices. Standards of evidence for claims of safety and therapeutic efficacy are rigorous because inappropriate product use may place human life at risk. However, equally demanding criteria for claims of cost-effectiveness of marketed technologies seem to be unnecessary because the consequence of error is principally a bad buy rather than patient harm. Concern exists about the validity of cost-effectiveness studies, the potential for bias, standards for the conduct of cost-effectiveness research, and the needs of managed care. The FDA should moderate its role in regulating cost-effectiveness claims of drugs and devices. This would foster information flow to healthcare providers and insurers and protect the FDA concern regarding false or misleading claims of effectiveness. Although the issues are applicable to both devices and drugs, we draw mainly from the field of pharmacoeconomics because this is where most of the policy has developed.
authors.affiliation: MEDTAP International, Inc., Bethesda, MD 20814, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Luce
authors.forename: A L
authors.initials: AL
authors.lastname: Hillman
mesh_terms: D003362:Cost-Benefit Analysis; D018795:Device Approval / Q000592:standards*; D017277:Drug Approval / Q000191:economics*; D006291:Health Policy; D008329:Managed Care Programs; D014481:United States; D014486:United States Food and Drug Administration